Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

263
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
263
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

436
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
436
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.7K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.7K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

638
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
638
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

399
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
399
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

318
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
318

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Updated Algorithm for the Management of Restless Legs Syndrome.

Mayo Clinic proceedings·2026
Same author

Neurostimulation for restless legs syndrome: A systematic review and meta-analysis.

Sleep medicine reviews·2026
Same author

Consensus roadmap on periodic leg movements during sleep: outcomes of the international PLMS taskforce.

Sleep·2026
Same author

Pharmacologic treatment data from chronic insomnia studies and the application to individuals with acute insomnia, a narrative review.

Sleep medicine reviews·2026
Same author

Restless Legs Syndrome: A Review.

JAMA·2026
Same author

Effectiveness and dose stability of opioids in patients with restless leg syndrome: 5-year findings from the National Restless Legs Syndrome Opioid Registry.

Sleep·2026

Related Experiment Video

Updated: Sep 22, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.4K

Treating Severe Refractory and Augmented Restless Legs Syndrome.

John W Winkelman1

  • 1Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Chest
|May 24, 2022
PubMed
Summary

Restless legs syndrome (RLS) management involves addressing triggers and using medications like alpha2-delta calcium channel ligands or dopamine agonists. For severe cases, switching treatments can improve RLS symptoms and sleep quality.

Keywords:
augmentationdopamine agonistsgabapentinguidelineironopioidpregabalinrestless legs syndrome

More Related Videos

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain
06:13

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain

Published on: March 1, 2024

1.1K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K

Related Experiment Videos

Last Updated: Sep 22, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.4K
Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain
06:13

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain

Published on: March 1, 2024

1.1K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K

Area of Science:

  • Neurology
  • Sleep Medicine

Background:

  • Restless legs syndrome (RLS) affects 2-3% of adults, worsening with age and in women, significantly impacting sleep and quality of life.
  • Common RLS triggers include iron deficiency, certain medications, and obstructive sleep apnea (OSA).

Purpose of the Study:

  • To outline current treatment strategies for Restless Legs Syndrome (RLS).
  • To discuss management of RLS, including addressing contributing factors and medication options.
  • To describe the phenomenon of augmentation associated with dopamine agonists and strategies to manage it.

Main Methods:

  • Review of current medical literature and treatment guidelines for RLS.
  • Discussion of pharmacological interventions, including alpha2-delta calcium channel ligands (A2Ds) and dopamine agonists (DAs).
  • Exploration of strategies for managing treatment-resistant RLS and dopamine agonist-induced augmentation.

Main Results:

  • Initial RLS treatment often involves iron supplementation, A2Ds (gabapentin, pregabalin), or DAs (pramipexole, ropinirole, rotigotine).
  • Approximately one-third of patients do not achieve adequate symptom relief with initial treatments.
  • Dopamine agonists (DAs) can cause augmentation, a worsening of RLS symptoms, necessitating a switch to A2Ds or opioids.

Conclusions:

  • Effective RLS management requires identifying and addressing contributing factors.
  • Switching from dopamine agonists to alpha2-delta calcium channel ligands or opioids can manage augmentation and improve RLS symptoms.
  • A gradual approach to medication adjustment is crucial for long-term RLS symptom relief and improved sleep.